| Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. | None |
| DJ-1, an oncogene and causative gene for familial Parkinson s disease, is essential for SV40 transformation in mouse fibroblasts through up-regulation of c-Myc. | None |
| Tumorigenesis in transgenic mice expressing the c-myc oncogene with various lymphoid enhancer elements. | None |
| Probing the binding affinity of small-molecule natural products to the G-quadruplex in C-myc oncogene by electrospray ionization mass spectrometry. | None |
| Expression of the N-myc proto-oncogene during the early development of Xenopus laevis. | None |
| Suppression of Aurora-A oncogenic potential by c-Myc downregulation. | None |
| role in mediating the oncogenic activity of Aurora-A | None |
| Immunohistochemical detection of c-myc oncoprotein in paraffin embedded tissues. | None |
| Myc/miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation. | None |
| Phosphorylation regulates c-Myc s oncogenic activity in the mammary gland. | None |
| [Progress of research on Proto-oncogene c-myc, c-myb in platelet diseases]. | None |
| [Presence of proteins and genes homologous to the c-myc proto-oncogene in Entamoeba]. | None |
| Quinolino-benzo-[5, 6]-dihydroisoquindolium compounds derived from berberine: a new class of highly selective ligands for G-quadruplex DNA in c-myc oncogene. | None |
| Studies indicate that many prognostic signatures reflect the activity of the MYC oncogene, which in turn regulates tumor metastasis through specific effects on cancer cell invasion and migration. | None |
| Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene. | None |
| endogenous Myc serves an essential and nonredundant role in coupling diverse intracellular oncogenic pathways to the tumor microenvironment | None |
| several miRNAs must be coordinately down-regulated to enhance critical oncogenes, such as Myc. | None |
| Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway. | None |
| Emerging Concepts in the Analysis of Transcriptional Targets of the MYC Oncoprotein: Are the Targets Targetable?. | None |
| ll patients with co-overexpression of bcl-2 and c-myc oncogenes will have PVU invasive carcinoma | None |